In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Nurix Therapeutics Inc (NASDAQ: NRIX) closed the day trading at $19.36 up 0.31% from the previous closing price of $19.3. In other words, the price has increased by $0.31 from its previous closing price. On the day, 0.82 million shares were traded. NRIX stock price reached its highest trading level at $19.54 during the session, while it also had its lowest trading level at $18.81.
Ratios:
For a better understanding of NRIX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.35 and its Current Ratio is at 5.35. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
On October 21, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $24.
On March 17, 2025, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $16.Leerink Partners initiated its Market Perform rating on March 17, 2025, with a $16 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 18 ’25 when Ring Christine sold 3,760 shares for $17.90 per share. The transaction valued at 67,314 led to the insider holds 50,897 shares of the business.
CHRISTINE RING bought 7,520 shares of NRIX for $136,939 on Dec 18 ’25. On Nov 24 ’25, another insider, Ring Christine, who serves as the Chief Legal Officer of the company, sold 37,600 shares for $17.07 each. As a result, the insider received 641,697 and left with 50,897 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRIX now has a Market Capitalization of 1962508416 and an Enterprise Value of 1116120320. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.45 while its Price-to-Book (P/B) ratio in mrq is 4.00. Its current Enterprise Value per Revenue stands at 13.337 whereas that against EBITDA is -4.303.
Stock Price History:
The Beta on a monthly basis for NRIX is 1.94, which has changed by 0.024416089 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, NRIX has reached a high of $22.50, while it has fallen to a 52-week low of $8.18. The 50-Day Moving Average of the stock is 26.72%, while the 200-Day Moving Average is calculated to be 63.16%.
Shares Statistics:
Over the past 3-months, NRIX traded about 1.78M shares per day on average, while over the past 10 days, NRIX traded about 1866250 shares per day. A total of 101.37M shares are outstanding, with a floating share count of 99.81M. Insiders hold about 1.53% of the company’s shares, while institutions hold 82.45% stake in the company. Shares short for NRIX as of 1765756800 were 13642687 with a Short Ratio of 7.67, compared to 1763078400 on 14076725. Therefore, it implies a Short% of Shares Outstanding of 13642687 and a Short% of Float of 15.160000000000002.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 12.0 analysts currently analyzing and rating the stock of Nurix Therapeutics Inc (NRIX).The consensus estimate for the next quarter is -$0.83, with high estimates of -$0.61 and low estimates of -$1.05.
Analysts are recommending an EPS of between -$2.48 and -$3.39 for the fiscal current year, implying an average EPS of -$3.1. EPS for the following year is -$3.41, with 13.0 analysts recommending between -$2.13 and -$4.46.
Revenue Estimates
For the next quarter, 16 analysts are estimating revenue of $16.72M. There is a high estimate of $22.5M for the next quarter, whereas the lowest estimate is $13.8M.
A total of 17 analysts have provided revenue estimates for NRIX’s current fiscal year. The highest revenue estimate was $108.78M, while the lowest revenue estimate was $70.4M, resulting in an average revenue estimate of $85.23M. In the same quarter a year ago, actual revenue was $54.55M
